Table 1.
Clinicopathological characteristics of (a) primary breast cancer patients and (b) metastatic breast cancer patients.
| (a) | |||||||||
|
Patient
No. |
Age |
Menopausal
Status |
Histology |
Pathology,
Tumor Size (pT) |
Lymph Node
Status (pN) |
Grade |
ER/PgR/HER2 2
Status (%) |
Ki67 (%) |
Neo-Adjuvant
Treatment and Response |
| 1 | 37 | Pre | IDC nos 1 | T2 | SN neg | 3 | -/-/- | 70 | NA 3 |
| 2 | 69 | Post | ILC | T1b(m) | N2a | X 4 | 95/1/- | 5 | Ctx-Epi + Txl(RP) |
| 3 | 46 | Pre | NET | T2 | N1(sn) | 3 | 80/80/- | 70 | NA |
| 4 | 34 | Pre | IDC | T2ypM1(L) | N1a | 3 | -/-/- | 60 | Beva + Txl (RP-Li; PD-T) |
| 5 | 52 | Post | IDC | T2 | N1(mi) | 2 | 90/2/- | 30 | NA |
| 6 | 73 | Post | IDC | T2 | N0(sn) | 2 | 90/3/- | 25 | NA |
| 7 | 75 | post | IDC nos | T1c | N1mi(sn) | 2 | 95/95/- | 20 | NA |
| 8 | 82 | Post | IDC | T3 | N0(sn) | 2 | 95/95/- | 20 | NA |
| 9 | 49 | Pre | R 5:IDC | T2 | N0(sn) | 2 | 95/95/- | 30 | NA |
| L: ILC | T2m | N1(sn) | 2 | 95/95/- | 15 | ||||
| 10 | 62 | Post | IDC | T1c | N1mi(sn) | 2 | 95/95/- | 20 | NA |
| 11 | 43 | Pre | IDC | T1c | N1a | 2 | 95/95/- | 20 | NA |
| 12 | 46 | Pre | IDC nos | T2 | N0(sn) | 2 | 95/95/- | 20 | NA |
| 13 | 49 | Pre | IDC nos | T1c | N1a | 2 | 90/90/- | 10 | NA |
| 14 | 51 | Pre | Ca papillary + NET | T2 | N1(sn) | 2 | 95/85/- | 20 | NA |
| 15 | 66 | Post | IDC | T2 | N0(sn) | 3 | 10/-/- | 50 | NA |
| 16 | 50 | Pre | ILC + NET | T3 | N1a | 3 | 90/90/- | 50 | NA |
| 17 | 32 | Pre | IDC apocrine | T2(m) | N1a | 3 | 80/-/- | 30 | NA |
| 18 | 76 | Post | IDC | T1c(m) | N3a | 3 | -/-/- | 25 | NA |
| 19 | 41 | Pre | IDC | T2 | N0 | 3 | -/-/- | 80 | Epi + Taxol(PD) |
| 20 | 78 | Post | IDC nos | T2 | N1mi(sn) | 2 | 95/70/- | 15 | NA |
| 21 | 79 | Post | IDC nos | T2(m) | N1a | 2 | 95/-/- | 22 | NA |
| 22 | 77 | Post | ILC | T2 | N1a | 2 | 90/40/- | 25 | NA |
| 1 IDC, infiltrating ductal carcinoma; DCIS, ductal carcinoma in situ; ILC, invasive lobular carcinoma; ILCI, lobular carcinoma in situ, Neuroendocrine tumor (NET); sn (sentinel lymph node); mi (micrometastasis); 2 ER, estrogen receptor; PgR, progesterone receptor, expressed in percentage; HER2status + positive or—negative; 3 NA, not applicable; Ctx: cyclophosphamide; Epi, epirubicin; Beva, bevacizumab; Txl: taxol; FEC, 5-fluorouracil, Epi, epirubicin, Ctx, cyclophoasphamide; 4 X, undetermined; 5 R: right side; L: left side. | |||||||||
| (b) | |||||||||
|
Patient
No. |
Age | Source of Cells |
Histology
on Original T |
Pathology,
pTNM Original T |
Grade |
ER/PgR/HER2 2
Status of the Original T (%) |
ER/PgR/HER2
Status of M Disease |
Previous
Treatments |
|
| 1 | 50 | Ascites | ILC 1 | NA 3 | NA | 95/95/+ | -/-/- | 5 CMF, Herc, Tam, AI, Pertuzumab, Dxt, CDDP, Gem | |
| 2 | 59 | Ascites | DCIS+ comedoCa |
pT1mN0 (m) | 3 | 70/60/- | -/-/- | Fulvestrant, Everolimus, Exem; Txl | |
| 3 | 67 | PE 6 | IDC | T3N+ | 3 | 95/30/- | -/-/- | NA (met at the diagnosis) | |
| 4 | 43 | PE | IDC | pT1cN1a | 2 | 80/50/+ | -/-/- | FEC, Herc, Cape, Lapatinb, Txl, CBDCA, CMF | |
| 1 IDC, infiltrating ductal carcinoma; DCIS, ductal carcinoma in situ; ILC, invasive lobular carcinoma; ILCI, lobular carcinoma in situ comedoca, comedocarcinoma; Neuroendocrine tumor (NET); sn (sentinel lymph node); mi (micrometastasis); 2 ER, estrogen receptor; PgR, progesterone receptor, expressed in percentage; HER2status + positive or—negative; 3 NA, not applicable; Ctx: cyclophosphamide; Epi, epirubicin; Beva, bevacizumab; Txl: taxol; FEC, 5-fluorouracil, Epi, epirubicin, Ctx, cyclophoasphamide; 4 X, undetermined; 5 R: right side; L: left side1 5 CMF, cyclophosphamide, methotrexate, 5-fluorouracil; Herc, Herceptin; Tam, Tamoxifen; A.I.: aromatase inhibitors; Exeme, exemestane; Dxt, Docetaxel; CDDP, Cisplatino; GEM, gemcitabine; Txl, Taxol; Cape: capecitabina; CBDCA: carboplatino; 6 PE: pleural effusion. | |||||||||